Form 4: Third Rock Ventures Sells Tango Therapeutics Shares in Multiple Transactions

Third Rock Ventures IV, L.P. sold shares of Tango Therapeutics (TNGX) in multiple transactions on July 24 and July 25, 2024.

Summary

• Third Rock Ventures IV, L.P., a significant shareholder of Tango Therapeutics, Inc. (TNGX), has reported the sale of common stock.
• On July 24, 2024, 200,000 shares were sold at a weighted average price of $9.8158, with prices ranging from $9.78 to $10.025.
• On July 25, 2024, an additional 100,599 shares were sold at a weighted average price of $9.8686, with prices ranging from $9.75 to $10.005.
• Following these transactions, Third Rock Ventures IV, L.P. directly holds 17,771,475 shares of Tango Therapeutics common stock.
• The sales were executed by Third Rock Ventures IV, L.P., with Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, signing on behalf of the entity.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as a major shareholder is reducing their position, which could indicate a lack of confidence or a strategic portfolio adjustment. However, it's a common practice for venture firms and doesn't necessarily reflect negatively on the company's fundamentals.

Negatives

• A major shareholder, Third Rock Ventures, is reducing its stake in Tango Therapeutics, which could be interpreted negatively by the market.

Risks

• Continued selling pressure from Third Rock Ventures could negatively impact the stock price of Tango Therapeutics.
• The market may react negatively to the reduction in a major shareholder's position.

Industry Context

Form 4 filings are standard disclosures for insiders selling shares, and the market will likely interpret the significance of these sales in the context of Tango Therapeutics' overall performance and future prospects.

Comparison to Industry Standards

• It's common for venture capital firms like Third Rock Ventures to gradually reduce their holdings in portfolio companies after they go public.
• The impact of these sales on TNGX's stock price will depend on the overall market sentiment and the company's performance relative to its peers in the biotechnology industry.
• Comparable companies in the biotechnology sector often experience similar insider selling patterns after initial public offerings or significant stock appreciation.

Stakeholder Impact

• Shareholders may react to the news of Third Rock Ventures selling shares.
• The stock price of Tango Therapeutics could be affected by these transactions.

Key Dates